Tuesday, Eli Lilly and Company (LLY) announced new long-term data from the LUCENT-3 open-label extension study in patients with moderately to severely active ulcerative colitis treated with Omvoh.
The study showed that 63.5 percent of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.
Moreover, the long-term safety profile in patients with moderately to severely active UC was consistent with the known safety profile of Omvoh with no new safety signals observed.
In the pre-market hours, LLY is trading at $966.06, down 0.23 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.